People · Operator
Named in public records as an officer, director or promoter · active 2008–2017 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $350.0M | $5.3B | 2009 |
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2009 |
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2009 |
| Achaogen Inc | — | Biotechnology | Series B | $89.7M | $396.9M | 2010 |
| Aria Diagnostics, Inc. | — | Biotechnology | Series C | $65.2M | $2.2B | 2010 |
| Ikaria Holdings Inc | — | Pharmaceuticals | Series C | $54.9M | $1.9B | 2008 |
Bryan E. Roberts at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bryan E. Roberts on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bryan Roberts | 2 | 18 |
| DAVID E. SHAW | 2 | 5 |
| Robert T. Nelsen | 2 | 5 |
| Christopher T. Walsh | 2 | 3 |
| Robert Langer | 1 | 36 |
| Robert Nelsen | 1 | 22 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| DAVID SHAW | 1 | 12 |
| John P Ryan | 1 | 11 |
| Alan Crane | 1 | 9 |
| Carl Weissman | 1 | 8 |
| Terry McGuire | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Robert Tepper | 1 | 7 |
| TERRANCE G. MCGUIRE | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| STEPHEN KNIGHT | 1 | 6 |
| JOSEPH C. COOK, JR. | 1 | 5 |
| PAUL Grayson | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.